新型2型糖尿病治疗药物SGLT-2抑制剂的临床研究进展

Clinical Research Progress of SGLT-2 Inhibitors,a Novel Treatment of Type 2 Diabetes

钠-葡萄糖协同转运蛋白2(SGLT-2)抑制剂是一类全新作用机制的降糖药物。它通过抑制葡萄糖在肾脏的重吸收,以增加尿糖的排泄,调节体内的血糖浓度,从而达到治疗2型糖尿病的目的。由于其独特的作用机制,SGLT-2抑制剂已经成为近年来降糖药物研究中最具发展潜力的新药。针对已上市和已进入临床研究的SGLT-2抑制剂中的重点化合物,综述其最新的临床研究进展。

Sodium - glucose co - transporter 2 （SGLT - 2） inhibitors are a class of antihyperglycemic a- gents with new mechanism of action. They can be used for treatment of type 2 diabetes by inhibiting the renal glucose reabsorption, thereby increasing the urinary glucose excretion, regulating the blood glucose levels. Because of the unique mechanism of action, SGLT - 2 inhibitors have become very promising for the development of new antihyperglycemic drugs. This paper reviewed the latest clinical research progress of the important SGLT - 2 inhibitors, which are already marketed or in clinical trials.